Chemokine Levels in Huntington's Disease
Author Information
Author(s): Edward Magnusson, Anna Lahiri, Nayana Krus, Ulrika Orth, Michael Tabrizi, Sarah J Björkqvist, Maria
Primary Institution: UCL Institute of Neurology, London, UK
Hypothesis
Altered chemokine profiles in plasma may correlate with disease progression in Huntington's disease.
Conclusion
Chemokines may be linked to the pathogenesis of Huntington's disease and could serve as biomarkers for tracking disease progression.
Supporting Evidence
- Five chemokines showed significant elevations in HD patients compared to controls.
- Chemokine levels correlated with clinical scores in HD patients.
- Three chemokines showed significant linear increases across advancing disease stages.
Takeaway
This study found that certain chemicals in the blood change as Huntington's disease gets worse, which might help doctors understand and track the disease better.
Methodology
Plasma chemokine levels were quantified using multiplex ELISA in two cohorts of HD patients and controls.
Potential Biases
Potential bias in sample processing as the operator was unaware of the disease state during analysis.
Limitations
The study may face challenges in using immune markers as reliable biomarkers due to variability influenced by infections and other factors.
Participant Demographics
Cohorts included HD mutation carriers and control subjects, with varying disease stages and ages.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website